Archive: 23/04/2019
Researchers devise a progression risk-based classification for patients with AWM
By analyzing data from hundreds of patients with asymptomatic Waldenström macroglobulinemia (AWM), researchers at Dana-Farber Cancer Institute have devised a risk model for determining whether patients with AWM have a low, ...
Apr 23, 2019
When designing clinical trials for Huntington's disease, first ask the experts
Progress in understanding the genetic mutation responsible for Huntington's disease (HD) and at least some molecular underpinnings of the disease has resulted in a new era of clinical testing of potential treatments. How ...
Apr 23, 2019